Yeaman Kevin J's Form 4 filing
Dolby Laboratories, Inc. (DLB) · filed Nov 22, 2021
- Accession no.
- 0001209191-21-066102
- Filed
- Nov 22, 2021
- Trade date
- Nov 18, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.64M. It was filed 4 days after the trade.
This filing was later replaced by the amendment 0001209191-21-066618 (Nov 23, 2021). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Yeaman Kevin JCIK 0001200469 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 18, 2021 | Class A Common Stock | MOption exerciseAcquired | +29,457 | $42.98 | +$1,266,061.86 | 62,352 | Indirect | |
| Nov 18, 2021 | Class A Common Stock | SSaleDisposed | −4,017 | $87.71F1 | −$352,331.07 | 58,335 | Indirect | |
| Nov 18, 2021 | Class A Common Stock | SSaleDisposed | −5,672 | $88.82F2 | −$503,787.04 | 52,663 | Indirect | |
| Nov 18, 2021 | Class A Common Stock | SSaleDisposed | −6,283 | $89.79F3 | −$564,150.57 | 46,380 | Indirect | |
| Nov 18, 2021 | Class A Common Stock | SSaleDisposed | −13,485 | $90.81F4 | −$1,224,572.85 | 32,985 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 18, 2021 | Class A Common Stock | MOption exerciseDisposed | −29,457 | $0.00 | $0 | 247,414 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The shares were sold in multiple transactions at prices ranging from $87.24 to $88.22, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F2
The shares were sold in multiple transactions at prices ranging from $88.34 to $89.15 inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F3
The shares were sold in multiple transactions at prices ranging from $89.37 to $90.34, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
- F4
The shares were sold in multiple transactions at prices ranging from $90.46 to $91.18, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.
Remarks
**All of the sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.**